for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Living Cell Technologies Ltd.

LCT.AX

Latest Trade

0.01AUD

Change

0.00(0.00%)

Volume

901,106

Today's Range

0.01

 - 

0.01

52 Week Range

0.01

 - 

0.02

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.01
Open
0.01
Volume
901,106
3M AVG Volume
26.70
Today's High
0.01
Today's Low
0.01
52 Week High
0.02
52 Week Low
0.01
Shares Out (MIL)
571.44
Market Cap (MIL)
6.42
Forward P/E
--
Dividend (Yield %)
--

Next Event

Living Cell Technologies Ltd Annual Shareholders Meeting

Latest Developments

更多

Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease

Living Cell Technologies Says Appointed Bernie Tuch As Interim Ceo

Living Cell Technologies Announces Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Living Cell Technologies Ltd.

Living Cell Technologies Limited (LCT) is an Australia-based biotechnology company. The Company is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The Company's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. It has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.

Industry

Biotechnology & Drugs

Contact Info

L 7 330 Collins St

MELBOURNE, VIC

3000

Australia

+61.3.86899997

http://www.lctglobal.com/

Executive Leadership

Bernie Tuch

Interim Chairman of the Board, Interim Chief Executive Officer

John Cowan

Head of Finance and Administration

Mark Andrew Licciardo

Company Secretary

Andrew Kelly

Non-Executive Director

Carolyn M. Sue

Non-Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
23.96
Price To Book (MRQ)
3.73
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-65.54
Return on Equity (TTM)
-58.04

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up